The LegalcommunityCH Awards 2026 took place at the AURA Event Saal in Zürich. The latest Edition brought together he excellence amongst in-house and law firms’ teams and professionals from the Swiss legal community. The winners
Niederer Kraft Frey (NKF) advised the buyers on all aspects of the acquisition (including the financing of the acquisition) of the OPAL Associates AG (OPAL) headquartered in Switzerland together with its subsidiaries in Germany and
Homburger advised Windward Bio, a private, clinical-stage biotechnology company, throughout completion of it USD 165 million series B Financing. In connection with the round, BG Partner represented lead investor OrbiMed, Novo Holdings, Blue Owl Capital and
Homburger advised Siegfried Holding in connection with the bridge financing for the acquisition of three drug substances sites in the US and Australia. The context On May 1, 2026, Siegfried Holding, a globally active Contract Development and
Niederer Kraft Frey (NKF) has advised Swiss global private banking group EFG International with respect to EFG International Finance (Luxembourg) S.à r.l.’s offering and issuance of inaugural EUR 500 million unsecured bonds 2026 – 2031 guaranteed by
Walder Wyss advised Liechtensteinisches Pfandbriefinstitut as issuer, as well as LGT Bank and Liechtensteinische Landesbank as member banks, dealers and managers, in connection with Liechtensteinisches Pfandbriefinstitut’s program and issuance of Liechtensteiner Pfandbriefe issued by
Homburger advised UBS AG and other dealers on the establishment of the Liechtensteiner Pfandbriefe Programme by Liechtensteinisches Pfandbriefinstitut AG, followed by an inaugural CHF 250 million bond issuance in April 2026.
Swiss food biotech startup Cosaic AG has closed a USD 6 million late seed financing round, with Walder Wyss advising on the transaction. The round attracted new investors including dsm-firmenich Ventures and Kickfund, alongside existing backers
Niederer Kraft Frey advised Balgrist Apotheke on the acquisition of the Minerva Pharmacy in Zurich from Schaller Apotheken, with a multidisciplinary team covering corporate, healthcare, and real estate matters.
Pestalozzi and Ropes & Gray advised Johnson & Johnson on a USD 500 million R&D co-funding agreement with Royalty Pharma to advance the development of JNJ-4804, an investigational co-antibody therapy targeting autoimmune diseases.
